Friday, March 11, 2016 1:39:48 PM
Safe Harbor Statementinformation contained in this press release may contain statements about future expectations, prospects or performance Hard To Hard To Diseases, Inc. Is the forward-looking statements within the meaning of the safe harbor commission treat pose under the Private Securities Litigation Reform Act of 1995 levitraprix.net . The words or phrases can be , expects , may , believe , estimate , forecast and similar words and expressions are intended forward-looking statements forward-looking statements. Hard to Treat Diseases Inc. Cautions you that forward-looking statements by or on behalf of Hard to Treat Diseases Inc. Not a guarantee of future performance. None of the information in this press release does not offer to sell securities offer to sell securities or investment advice of any kind. Treat Diseases, Inc. Diseases Inc. Could cause actual results to differ materially from the anticipated in such forward – looking statements as a result of various important factors heavily, some of which beyond outside the control Treat Diseases Inc. In addition to the in hardware discussion order diseases Inc. Press releases, public address announcements and explanations of Hard to Treat Diseases, Inc. Management, including, but not limited to, Hard To Diseases Inc estimate of the sufficiency of its existing capital resources, Hard To Diseases Inc ability to raise additional capital to finance future operations treat, hard to treat treat diseases Inc the ability to existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts awarded contracts to tough game against diseases Inc capability. Deal repay all such forward-looking statements are current only as of the date on which such statements were made Hard to Treat Diseases Inc. Undertakes no obligation to publicly update forward-looking statements in order to after the date on which such statements occur, or the occurrence of unanticipated events.
Long-termDiseases Clinical Update on Therapeutic effects of combined treatment with ribavirin and tiazofurin TreatHard to treat Diseases Chief Scientist with its Slavica BioChem subsidiary, provided Sanja Pekovic updates on recent clinical trials with animals issues relating to the use of ribavirin and tiazofurin for the potential treatment of multiple sclerosis . Says reported: ‘It is now universally accepted that axonal injury begins at an early stage in MS, and likely accounts for clinical progression later be seen in the course of the disease, suggesting that early, aggressive treatment is essential to suppress. Long-term progression of disability researchers IBISS group tested the effect of combined treatment with ribavirin and tiazofurin administered during the effector phase of the disease. Continue reading ?
http://ritawestea.com/2016/03
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM